Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy
Alpha-synuclein is a potential biomarker in the serum and CSF of patients with intractable epilepsy
复制标题
DOI：
10.1016/j.seizure.2015.02.007
复制
发表时间：
2015-04-01
影响因子：
3
通讯作者：
Xi, Zhiqin
中科院分区：
文献类型：
--
作者：
Hu, Rong;Luo, Jin;Xi, Zhiqin
目的：难治性癫痫是一种以反复发作和细胞内α-突触核蛋白（α S）沉积为特征的脑部疾病;然而，这种蛋白质积累的神经生物学基础仍然知之甚少。这是第一个研究旨在评估是否在血清和脑脊液（脑脊液）中的aS浓度的增加可以作为一个标志物的aS沉积在大脑和癫痫的诊断。方法：本次调查纳入67例癫痫患者（40与难治性癫痫，13与新诊断的癫痫，14与非难治性癫痫）。CSF和血清样品从每个病人收集和进行了评估，通过ELISA.Results：它被建立，在CSF和血清中的aS浓度升高，在癫痫患者，作为对照。亚组分析结果显示，难治性癫痫患者血清和脑脊液中aS水平升高（CSF：11.12 +/- 4.18 ng/ml;血清：52.93 +/- 22.11 ng/ml），而新诊断的患者组之间无差异。（CSF：34.998 +/- 14.96 ng/ml;血清：7.77 +/- 3.41 ng/ml）和非难治性癫痫（CSF：8.93 +/- 4.83 ng/ml;血清：34.11 +/- 17.53 ng/ml）。总之，我们发现血清和脑脊液中aS含量的升高可能有助于难治性癫痫的鉴别;因此，AS率的测定可作为临床评估中有价值的预后指标。(C)2015年英国癫痫协会。由爱思唯尔有限公司出版。保留所有权利。
Purpose: Intractable epilepsy is a brain disorder characterized by recurrent seizures and intracellular alpha-synuclein (alpha S) deposits; however, the neurobiological basis of this protein accumulation is still poorly understood. This is the first study aiming to assess whether the increase of aS concentrations in the serum and CSF (cerebrospinal fluid) could serve as a marker for aS deposition in the brain and diagnosis of epilepsy.Methods: This investigation enrolled 67 epileptic patients (40 with intractable epilepsy; 13 with newly diagnosed epilepsy, and 14 with non-intractable epilepsy). CSF and serum samples were collected from each patient and were assessed by ELISA.Results: It was established that the concentration of aS in the CSF and serum was elevated in the epilepsy patients, as compared to the control. However, the results of the subgroup analysis revealed that levels of aS in the serum and CSF were increased in the intractable epileptic patients (CSF: 11.12 +/- 4.18 ng/ml; serum: 52.93 +/- 22.11 ng/ml), whereas there was no difference in the groups with the newly diagnosed (CSF: 34.998 +/- 14.96 ng/ml; serum: 7.77 +/- 3.41 ng/ml) and non-intractable epilepsy (CSF: 8.93 +/- 4.83 ng/ml; serum: 34.11 +/- 17.53 ng/ml).Conclusion: Overall, we found that the rise of the aS content in the serum and CSF may facilitate the identification of intractable epilepsy; therefore, the determination of aS rates may serve as a valuable prognostic marker in the clinical assessment. (C) 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.